💊 Lanthanum carbonate is a non-calcium, non-aluminium phosphate binder used to control serum phosphate in patients with chronic kidney disease (CKD). It reduces the risk of vascular calcification compared to calcium-based binders.
📖 About
- Always check the BNF link here for up-to-date prescribing guidance.
- Used when dietary phosphate restriction alone is insufficient.
⚙️ Mode of Action
- Lanthanum binds dietary phosphate in the gastrointestinal tract, forming insoluble complexes that are excreted in faeces, thereby lowering serum phosphate.
🎯 Indications
- Hyperphosphataemia in patients with CKD on haemodialysis or CAPD (continuous ambulatory peritoneal dialysis).
- Hyperphosphataemia in CKD patients not on dialysis with serum phosphate >1.78 mmol/L despite low-phosphate diet.
💊 Dose
- Initial: 1.5–3 g daily in divided doses with or immediately after meals.
- Adjust every 2–3 weeks according to serum phosphate levels.
- Maximum dose often limited by gastrointestinal tolerance rather than efficacy.
⚠️ Interactions
- Lanthanum decreases absorption of Ciprofloxacin — give ciprofloxacin at least 2 hours before or after lanthanum.
- Minimal systemic absorption; few drug–drug interactions compared to aluminium/calcium binders.
🚫 Contraindications
- Gastrointestinal obstruction, ileus, or severe bowel disease (risk of complications).
🤒 Side Effects
- GI upset most common: constipation, diarrhoea, abdominal pain, nausea, vomiting.
- Headache, dizziness, electrolyte disturbances (rare).
- Lanthanum is minimally absorbed, so systemic toxicity is rare.
💡 Pearls
- Preferred over aluminium-based binders (avoids aluminium toxicity) and calcium-based binders (less vascular calcification risk).
- Chewable tablets must be chewed thoroughly to be effective.
- Monitor serum phosphate and calcium regularly in CKD patients.
- Part of “mineral bone disorder” management in CKD, alongside vitamin D analogues and parathyroid hormone control.
📚 References